Details

Autor(en) / Beteiligte

• Zack, Travis I
• Schumacher, Steven E
• Carter, Scott L
• Cherniack, Andrew D
• Saksena, Gordon
• Tabak, Barbara
• Lawrence, Michael S
• Zhang, Cheng-Zhong
• Wala, Jeremiah
• Mermel, Craig H
• Sougnez, Carrie
• Gabriel, Stacey B
• Hernandez, Bryan
• Shen, Hui
• Laird, Peter W
• Getz, Gad
• Meyerson, Matthew
• Beroukhim, Rameen

Titel

Pan-cancer patterns of somatic copy number alteration

Ist Teil von

• Nature genetics, 2013-10, Vol.45 (10), p.1134-1140

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Rameen Beroukhim and colleagues analyzed somatic structural alterations in 12 tumor types. Whole-genome doubling was found in over a third of all cancers, associated with TP53 mutation. Fifteen new significantly mutated candidate driver genes were found associated with recurrently amplified or deleted regions. Determining how somatic copy number alterations (SCNAs) promote cancer is an important goal. We characterized SCNA patterns in 4,934 cancers from The Cancer Genome Atlas Pan-Cancer data set. Whole-genome doubling, observed in 37% of cancers, was associated with higher rates of every other type of SCNA, TP53 mutations, CCNE1 amplifications and alterations of the PPP2R complex. SCNAs that were internal to chromosomes tended to be shorter than telomere-bounded SCNAs, suggesting different mechanisms underlying their generation. Significantly recurrent focal SCNAs were observed in 140 regions, including 102 without known oncogene or tumor suppressor gene targets and 50 with significantly mutated genes. Amplified regions without known oncogenes were enriched for genes involved in epigenetic regulation. When levels of genomic disruption were accounted for, 7% of region pairs were anticorrelated, and these regions tended to encompass genes whose proteins physically interact, suggesting related functions. These results provide insights into mechanisms of generation and functional consequences of cancer-related SCNAs.